Phase 2 Study of Ruxolitinib in Chronic Myelomonocytic Leukemia Shows Potential for Improved Outcomes
A Phase 2 expansion study is underway to evaluate the efficacy of ruxolitinib in patients with CMML.
Asset / Drug
Drug and asset intelligence for Incyte with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.